Latest Conference Coverage

The chief medical officer of Clene Nanomedicine detailed CNM-Au8, their novel investigational drug currently being assessed in multiple trials for patients with multiple sclerosis and other neurodegenerative diseases.

Data suggests that access to endovascular thrombectomy centers within 15 minutes is limited to less than one-fifth of the population, pointing to a need for improved access and bypass methodologies.

The director of Pediatric MS and Wellness at the Mellen Center and assistant professor of neurology at Cleveland Clinic Lerner College of Medicine describes her study on shared medical appointments and the intricacies of integrating them into the common care realm.

The assistant professor of neurology at the Lerner College of Medicine and neurologist at Luo Ruvo Center for Brain Health, both of Cleveland Clinic, discussed the challenges of current measurements and the need to adjust the reading of progressive MS.

The director of the Partners Pediatric MS Center at Massachusetts General Hospital for Children provided insight on the consequences of incomplete relapse recovery in multiple sclerosis.

The assistant professor of neurology at the Lerner College of Medicine and neurologist at Luo Ruvo Center for Brain Health, both of Cleveland Clinic, spoke to the importance of preventing progression in MS and treating the non-inflammatory aspects of the disease.

The associate professor in the department of neurology at the University of Colorado and neurologist at Advanced Neurology of Colorado discussed the advantages of cladribine and details of the ongoing CLICK-MS study.

Similar effects were observed for each proxy SMPS component when compared with placebo.

When performed by itself, endovascular therapy had greater rates of intracranial hemorrhage compared to a combination of both endovascular therapy and intravenous thrombolysis.

Data from the CLARITY extension trial suggest that the durability of treatment with cladribine extended beyond 24 months in those with relapsing-remitting multiple sclerosis.

Recovery status may be a useful tool to predict long-term outcomes in patients with relapsing forms of multiple sclerosis.

The investigational MS therapy is currently under review with the FDA, with a PDUFA date set for June 2020.

Compared with patients who initially received interferon treatment, those given ocrelizumab had superior disability progression after a 6-year follow-up.

Patients with a disease duration of <16 years demonstrated a significantly greater reduction in risk for confirmed disability progression (CDP) at 3 and 6 months.

Phase 2 STOP-AUST data suggest that the antifibrinolytic agent may be able to reduce ICH in spot sign positive patients with stroke when administered within 2 to 3 hours of onset, warranting further study.

New study data from ISC 2020 suggest that patients with stroke can be effectively treated with tenecteplase at a lower dose of 0.25 mg/kg, reducing the need for mechanical clot removal.

Stroke patients experienced higher rates of thrombolysis as well as faster alarm to treatment times when mobile stroke units were present.

The composite primary end point of the study occurred in 9.6% of patients in the lower-target LDL-C group compared with 12.9% in the higher target group.

Despite missing the primary end point, data from a subset of patients suggest that the novel peptide may be beneficial in those who have not received alteplase.

Despite the conventional need for patients to travel to MRI devices, the use of a point-of-care, portable scanner has proven to be a feasible method of acquiring clinically useful images.

Patients 65 and under were more likely to develop seizures following a stroke than older patients.

The beneficial impact on stroke risk appeared to be greater in patients age 79 and younger than in the older patients examined.

The model may help clinicians enact preventative measures for those with migraine with aura at an early stage.

The professor of neurology and epilepsy specialist at the Cleveland Clinic Lerner College of Medicine discussed the difficult treatment decisions faced when undergoing epilepsy surgery.

The director of the Pediatric Epilepsy Program and an MD candidate at Weill Cornell Medicine detail the steps needed to take to improve outcomes in status epilepticus.

Page B. Pennell, MD, president of the American Epilepsy Society, shared her thoughts on the epilepsy treatment landscape, managing women with epilepsy, and the need for multidisciplinary involvement and communication.

The president of the American Epilepsy Society and director of epilepsy research at Brigham and Women’s Hospital outlined the state of epilepsy care and what we can expect in 2020.

The director of the Pediatric Epilepsy Program is joined by an MD candidate from Weill Cornell Medicine to discuss the protocol used to treat patients with status epilepticus.